Social Media Influencer Fair Market Value in Life Sciences: Structuring Compensation to Withstand Regulator Scrutiny

Executive Summary

The use of social media influencers to expand awareness and promote prescription drugs, medical devices and health-related products has grown rapidly, giving companies new channels via which to engage with patients and caregivers. Regulators have historically focused on content and dissemination requirements for promotional communications, but they have also emphasized the need to structure related financial arrangements appropriately. The Office of Inspector General of the U.S. Department of Health and Human Services (OIG) has identified fair market value (FMV) and compensation structure as key considerations under the federal Anti-Kickback Statute (AKS) in its Special Fraud Alert on Speaker Programs (November 2020) and its Compliance Program Guidance for Pharmaceutical Manufacturers.[1] Companies should evaluate influencer arrangements not only for promotional compliance but also for alignment with FMV, AKS and related fraud and abuse requirements. This client alert describes practical steps for structuring and governing social media influencer compensation.

Overview

Life sciences manufacturers increasingly engage influencers (ranging from healthcare professionals to patient advocates and lifestyle content creators) to support a variety of commercial and educational objectives. These influencer arrangements commonly include disease awareness campaigns, patient experience storytelling, branded product promotion/unbranded messaging and multichannel marketing amplification across platforms such as Instagram, Facebook, TikTok and YouTube.

Influencer engagements often involve payments tied to content creation, audience reach, duration and other engagement metrics such as exclusivity and usage rights. These influencer arrangements present challenges beyond those faced in traditional promotional channels, including:

• Less standardized pricing;
• Greater variability in scope and deliverables; and
• Increased risk that compensation may be implicitly tied to the value or volume of referrals or product utilization, particularly involving federal healthcare program beneficiaries.

Companies should be able to demonstrate that influencer payments (1) reflect FMV for bona fide services, (2) are not tied to prescribing, utilization or product performance, and (3) are supported by defensible methodologies and documentation. FMV for influencer arrangements may encompass not only the time and effort associated with discrete deliverables (e.g., video recording, case study preparation), but also the value of the influencer’s network and audience authority, particularly when those metrics inform the scope and expected reach of their work.

The data inputs used to support such FMV determinations change frequently, with engagement metrics, audience behavior and platform algorithms evolving rapidly over time. Changing inputs can materially affect valuation assumptions and underscore the need for more frequent updates to underlying data and pricing inputs. Companies may benefit from engaging independent valuation experts to support and refresh FMV analyses and help ensure that compensation remains aligned with current market conditions.

Enforcement Landscape and Emerging Risk Areas

Recent regulatory activity includes separate actions addressing direct-to-consumer advertising. In September 2025, the White House issued a presidential memorandum addressing misleading direct-to-consumer advertising. Separately, the U.S. Food and Drug Administration (FDA) issued warnings and untitled letters addressing promotional communications that, in the FDA’s view, omitted or minimized risk information. Those warnings and untitled letters state the FDA’s position on specific communications; they are not findings of liability.[2] The FDA is also considering a proposed rule, targeted for publication in December 2026, that would eliminate the existing “adequate provision” standard and require manufacturers to provide key risk and safety information within broadcast direct-to-consumer advertisements. If finalized, the rule would apply prospectively only to advertisements disseminated after the final rule takes effect; manufacturers should track the docket rather than plan against the December 2026 target date.[3]

The Federal Trade Commission (FTC) has continued to focus on influencer endorsements and health-related claims. The FTC’s Health Products Compliance Guidance states, for example, that the agency’s enforcement reaches a wide variety of marketing techniques, such as the internet, social media and influencer marketing, and other digital content.[4] The FTC’s Endorsement Guides also include specific directions about when and what disclosures are required where there is a “material relationship” between a promotional activity sponsor and an influencer, i.e., a relationship that “might affect the weight or credibility of the endorsement” and would not be reasonably expected by consumers. This includes compensation, free products or other benefits provided to healthcare professionals, patients or other influencers in connection with promotional content.[5]

Within this environment, influencer engagements raise several interconnected risks:

• Misleading or incomplete product labeling risk disclosure, particularly on short-form or character-limited platforms.
• Inappropriate content or claims about the uses of the product, including informal or unscripted influencer communications.
• Misinformation through user engagement, reposting and platform dynamics, including the resharing of content without original disclosures or context; the influence of user comments that may introduce or reinforce inaccurate claims; and the repackaging of content across formats (e.g., clips, screenshots, memes or cross-platform sharing) that can strip away key risk or indication information.
• Reputational risk driven by influencer conduct, messaging or public perception.

A compliance framework related to these risks should also address compensation and include appropriate governance and oversight of influencer engagements.

The Role of FMV in Influencer Arrangements

An independent FMV assessment provides a documented basis for setting influencer compensation by reference to the services, deliverables and market inputs supporting the payments. It can help companies demonstrate that influencer compensation reflects the value of bona fide services rather than the potential commercial impact of the promotion. As regulatory scrutiny of digital promotion increases, this operational support has become increasingly important.

Establishing FMV in the context of influencer engagements presents unique challenges when compared to determining FMV for more traditional service arrangements. Compensation in this space is often influenced by factors such as audience size, engagement metrics, platform reach and perceived brand value. These variables are inherently less standardized and may not directly correlate to discrete, measurable services. They increase the risk that payments could be interpreted as tied to product visibility, demand generation or other commercial outcomes, rather than to the underlying services performed.

To address these challenges, companies should take a structured approach to defining and valuing influencer services. Metrics such as follower count and engagement rate are key drivers of compensation, as they inform the expected reach and visibility of the services provided. These metrics can be used to group influencers into “tiers” (e.g., nano influencers, micro influencers, mid-tier influencers, macro influencers, and mega influencers), creating consistent FMV ranges across similar influencer arrangements. Companies should define each tier by follower-count bands set by the company, document those bands in their FMV methodologies, and apply them consistently. Companies should also clearly identify the specific deliverables expected under the influencer arrangement, such as the number and type of posts, content development responsibilities or participation in broader campaigns. Reach-based metrics legitimately inform the market value of influencer services, but companies should ensure that compensation is ultimately tied to the influencer’s tier, expected deliverables and the nature of the services performed (e.g., the type of content, the number of posts/reels/stories, the duration of the engagement, exclusivity requirements and content creation responsibilities) rather than to the volume or value of referrals or product utilization. To help mitigate compliance risk, companies should ensure that compensation is set in advance based on the influencer’s tier and expected deliverables, applied consistently across similar influencer arrangements, not paid until proof of performance is confirmed, and not adjusted or contingent upon actual prescribing, product sales, utilization or other product-specific outcomes.

Companies may consider incorporating a combination of market analyses, cost-based approaches and, when appropriate, independent valuation support to substantiate FMV. Regardless of the methodology used, companies should ensure that the assumptions and conclusions are well-documented and consistently applied across similar influencer arrangements.

Documentation plays a central role in supporting the defensibility of influencer compensation. Written agreements should clearly describe the scope of services and associated deliverables, and companies should maintain evidence demonstrating that services were performed in accordance with those terms. Where influencer arrangements involve physicians or other covered recipients (e.g., physician assistants, nurse practitioners and so on), companies should also ensure they are tracking and reporting payments as required under the Open Payments program. Documentation gaps alone can create risk even where the underlying influencer arrangement is substantively compliant. Where federal healthcare program beneficiaries are involved, downstream consequences may include AKS exposure and potential False Claims Act exposure. Absent this level of rigor, even appropriately structured influencer arrangements may be vulnerable to challenge, particularly in an environment where regulators remain focused on the intersection of compensation, promotion and compliance.

FMV Compliance Considerations and Governance Framework

The evolving regulatory landscape has three practical implications for companies engaging and compensating influencers.

1. Identify and Manage High-Risk Areas: Companies should proactively assess and mitigate risks associated with both the content and compensation under influencer arrangements.
2. Monitor, Train and Respond: As part of a broader governance framework, companies should establish protocols for monitoring influencer content and engagement and processes for reviewing and responding to issues related to such engagements.
3. Integrate FMV into the Compliance Lifecycle: FMV considerations should be embedded throughout the lifecycle of influencer engagements, including:

• Pre-engagement FMV assessment and structuring;
• Ongoing monitoring of services and deliverables; and
• Post-engagement validation and periodic reassessment of valuation assumptions.

Influencer arrangements can generally be absorbed into infrastructure companies already have in place — including promotional and nonpromotional material review, third-party vendor risk assessment and procurement review — rather than requiring companies to create a parallel process.

Key Takeaways

The increasing use of influencers in life sciences promotion creates strategic opportunities and compliance challenges. Existing frameworks established by the FDA and FTC provide guidance on content, disclosure and truthfulness, while compensation structures underlying promotional activities remain an important area of regulatory focus. Key actions companies can take include:

• Setting influencer compensation in advance by tier and deliverable, and documenting the basis of compensation decisions.
• Refreshing FMV inputs on a defined cadence as engagement metrics and platform algorithms change.
• Routing influencer content through existing material review processes, rather than building a de novo/parallel process.
• Obtaining proof-of-performance documentation before releasing payment and storing it in a central document repository.
• Considering independent valuation support for higher-tier or multiplatform influencer arrangements.

These measures can help companies distinguish bona fide service compensation from promotional incentives that may influence healthcare decision-making or patient perception and will support defensible governance with respect to influencer arrangements.